Camargo
DECEMBER 22, 2021
In addition, the size and complexity of a development program can vary significantly depending on product characteristics, market dynamics, and regulatory pathway. This is a key factor in designing Phase 2 and 3 trials. It can also help identify which of these factors are most critical to commercial success. Clinical Pharmacology.
The Pharma Data
MARCH 8, 2021
The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We Ridgeback markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 25, 2021
Real-world evidence is woven into the fabric of how we innovate and advance care for patients with breast cancer, supporting our randomized clinical trials,” said Chris Boshoff, M.D., However, this observational analysis differs from the randomized clinical trial in several ways. About the IBRANCE Real-World Evidence Program.
The Pharma Data
MARCH 25, 2021
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Gilead Sciences, Inc.
The Pharma Data
FEBRUARY 8, 2021
Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported. IBRANCE may impair fertility in males and has the potential to cause genotoxicity. of IBRANCE-treated patients had ILD/pneumonitis of any grade, 0.1%
Camargo
APRIL 20, 2021
Sponsors can select the patient population and leverage companion diagnostics, and nonclinical study requirements such as genotoxicity and carcinogenicity studies can often be waived or delayed to later stages of development, especially for end-stage cancer therapies. Secure the Right Development and Regulatory Partners.
The Pharma Data
APRIL 7, 2021
The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. All filings are based on data from the Phase 3 ASCENT study. Trodelvy Boxed Warning. The Trodelvy U.S. About the ASCENT Study.
Expert insights. Personalized for you.
169 
Let's personalize your content